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a  b  s  t  r  a  c  t
ES-62,  a glycoprotein  secreted  by  the  ﬁlarial  nematode  Acanthocheilonema  viteae,  has  been  shown  to
modulate  the  immune  system  through  subversion  of  signal  transduction  pathways  operating  in  various
immune  system  cells.  With  respect  to  human  bone  marrow-derived  mast  cells  (BMMCs),  ES-62 was
previously  shown  to inhibit  FcRI-mediated  mast  cell  functional  responses  such  as degranulation  and
pro-inﬂammatory  cytokine  release  through  a  mechanism  involving  the  degradation  of  PKC-. At  the
same  time,  it was  noted  that  the  worm  product  was  able  to  degrade  certain  other  PKC  isoforms  but  the
signiﬁcance  of this  was  uncertain.  In  this  study,  we  have  employed  PKC  isoform  KO  mice  to  investigate
the  role of  PKC-,  - -, and - in  mouse  BMMCs  in order  to establish  their  involvement  in mast  cell-
mediated  responses  and  also,  if their  absence  impacts  on ES-62’s  activity.  The  data  obtained  support
that  in  response  to antigen  cross-linking  of  IgE bound  to FcRI,  pro-inﬂammatory  cytokine  release  is
controlled  in  part  by  a partnership  between  one  conventional  and one  novel  isoform  with PKC-  and  -
acting  as  positive  regulators  of  IL-6 and TNF-  production,  while  PKC-  and   act  as  negative  regulators
of  such  cytokines.  Furthermore,  ES-62  appears  to target  certain  other  PKC  isoforms  in  addition  to  PKC-
to  inhibit  cytokine  release  and  this  may  enable  it to  more  efﬁciently  inhibit  mast cell  responses.
© 2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
The Protein kinase C (PKC) family comprises a number of
phospholipid-dependent serine/threonine protein kinases that
play critical roles in signal transduction pathways within a cell,
controlling fundamental functions such as cell growth, prolifera-
tion, differentiation and apoptosis [1,2]. Currently, up to 10 PKC
isoforms have been identiﬁed in mammals, and have been shown
to have extensive tissue distribution and cellular localization [1,3].
PKC family members are divided into three main subsets based on
their structure and lipid requirements for activation: (a) calcium
and diacylglycerol (DAG)-regulated conventional isoforms (cPKCs:
, I, II and ); (b) calcium-independent, DAG-dependent novel
∗ Corresponding author.
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isoforms (nPKCs: , , , and ); (c) the atypical isoforms which are
both calcium and DAG independent (aPKC:  and 	/
) [3–9].
Mast cells constitute a heterogeneous cell population that
exhibits distinct phenotypic and functional properties [10–12],
with differences in PKC isoform expression being reported to exist
both between species and in mast cell subtypes within a species
[13–15]. For example, the rat mast cell line RBL-2H3 expresses
a set of PKC isoforms distinct from that of mouse bone marrow-
derived mast cells (BMMCs) and human mast cells (HMCs) [13–15].
Conventional PKC isoforms have been implicated in differential
mast cell responses such as degranulation and the release of
pro-inﬂammatory mediators like cytokines, prostaglandins and
leukotrienes [14–16]. Thus, in the context of antigen stimulation,
genetic knockout studies have demonstrated the importance of
PKC- in mast cell degranulation [16] whilst PKC- has been impli-
cated as playing a critical role in the production of cytokines [14].
It is the release of such pro-inﬂammatory mediators following the
http://dx.doi.org/10.1016/j.imlet.2015.09.001
0165-2478/© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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activation of mast cells via cross-linking of FcRI that results in
the pathological consequences of mast cell activation and is largely
responsible for the symptoms associated with allergic disorders
[11,17].
The phosphorylcholine (PC)-containing secreted glycoprotein,
ES-62, derived from the ﬁlarial nematode Acanthocheilonema viteae
has previously been shown to possess immunomodulatory prop-
erties via subversion of signal transduction pathways operating in
various immune system cells such as macrophages, B cells and den-
dritic cells [18] and reﬂecting this, it exhibits therapeutic potential
in models of inﬂammatory disease such as asthma, contact hyper-
sensitivity and rheumatoid arthritis [19]. In addition, ES-62 has
been shown to inhibit human mast cell function and consequent
allergic responses by selectively targeting key signals involved in
degranulation and cytokine release such as calcium mobilization
and the expression of PKC- [13]. Likewise, ES-62-mediated down-
regulation of PKC- has been demonstrated in a range of mouse
mast cell subtypes (bone marrow-derived mucosal-type mast cells;
BM-connective tissue mast cells and peritoneal-derived mast cells)
and downregulation of PKC- in BMMCs, ultimately rendering the
cells hypo-responsive to subsequent stimuli [10]. An additional
ﬁnding in the human mast cell study was that ES-62 reduced the
expression level of PKC isoforms other than PKC-, namely PKCs
-, -, -	 and – [13] although the signiﬁcance of this for ES-62’s
immunomodulatory activity is uncertain. The aim of this study was
thus to investigate the role of various PKC isoforms (, , , ) in
BMMC  functional responses through the use of PKC-isoform deﬁ-
cient (PKC isoform−/−) mice and to determine whether the absence
of a particular isoform impacts on ES-62 activity.
2. Materials and methods
2.1. Mice and reagents
Both male and female BALB/C mice aged between 6 and 8 weeks
old that had been bred and maintained at the University of Strath-
clyde animal unit were used to generate bone-marrow derived
mast cells (BMMCs) for certain aspects of this study. Additionally
for PKC isoform−/− studies, PKC- (C57BL/6-Sv129 background),
- (129/Sv/129/Ola background), - (B10.PL background) and –
(C57BL/6Jax background) deﬁcient mice in conjunction with their
age and sex matched wild-type controls were used to generate
BMMCs. PKC-−/− and PKC-−/− mice were generated as previ-
ously described [20,21]. Each set of PKC knockout (KO) mice and
their wild-type (WT) counterpart were bred and maintained at
the speciﬁc laboratory group’s animal unit before the bones were
harvested and shipped to the University of Strathclyde. It should
be noted that we observed variability in the stimulated cytokine
response of mast cells derived from the different WT  control mice:
their different origins and facilities they were raised in, in addi-
tion to differences in genetic background, presumably represent
likely contributors to this. All animals used were pathogen-free and
all procedures were conducted in accordance with Home Ofﬁce,
U.K. animal guidelines and with the approval of the local ethical
committees.
2.2. Bone marrow-derived mast cells (BMMCs)
Intact femur and tibia bones were dissected from mice or
shipped from collaborators on ice within 24 h and soaked in 70%
ethanol to remove ﬁbroblasts and connective tissue before the
ends of each femur and tibia were snipped and single cell suspen-
sions made from the bone marrow by ﬂushing cold RPMI complete
(RPMI 1640 with 10% HI FCS, 2 mM l-glutamine, 100 U/mL Penicillin
and 100 g/mL streptomycin) through one end of the bone with
a 23 gauge sterile needle. The resulting cell suspension was then
mixed gently using a 22 gauge sterile needle attached to a syringe
to remove any clumps of cells before passing the cell suspen-
sion through a sterile BD sieve. The mixture was then centrifuged
at 400 g for 5 min  before the supernatant was discarded and the
remaining cell pellet was  re-suspended in fresh culture medium
and cells counted using a haemocytometer. BMMCs were derived
by culture of bone marrow progenitors at 0.5 × 106/mL  in RPMI
with 10% HI FCS, 2 mM l-glutamine, 100 U/mL Penicillin, 100 g/ml
Streptomycin, 1 mM sodium pyruvate, 10 mM HEPES, and 50 M -
mercaptoethanol supplemented with conditioned growth medium
from KLS-C (1%; SCF) and TOP3 (3%; IL-3) cell lines. Cells were incu-
bated at 37 ◦C/ 5% CO2 for 3–6 weeks in total. BMMCs  were counted
and provided with fresh medium and cytokines and transferred to
a fresh ﬂask twice a week. After 3–4 weeks maturation, the cells
were tested for their expression of the cell surface markers c-kit,
FcRI to ascertain their identity as mature mast cells.
2.3. Mast cell phenotyping by ﬂow cytometry
BMMCs  were phenotyped by ﬂow cytometric analysis and the
presence of the cell surface markers, c-kit and FcRI, were con-
ﬁrmed. Brieﬂy, cells were counted (0.1 million cells per sample),
washed 1X with cold PBS and re-suspended in 50 L of FACS buffer
(PBS containing 2% BSA (W/V) and 2 mM  EDTA) per sample. The
aliquots of cells were then incubated with 50 l of ﬂuorescently-
tagged antibodies to conﬁrm the presence of the cell surface
markers for 30 min  in the dark on ice. After labelling, cells were
washed a ﬁnal time with 3 ml  FACS buffer at 400 g for 5 min  before
being re-suspended in 250 l of FACS buffer for ﬂow analysis using
a Becton Dickinson BD FACS CANTOTM ﬂow cytometer. Analysis was
performed on a minimum of 10, 000 events. Flowjo software (Tree
Star Inc., OR, USA, version 7.6.3) was used for ﬁnal analysis of the
ﬂow cytometry data.
2.4. Mast cell stimulation
Unless otherwise stated, mast cells were plated at
1 × 106cells/mL on a 12 well sterile tissue culture plate. Cells
were then sensitized with anti-DNP IgE (0.5 g/mL) in the pres-
ence or absence of ES-62 (2 g/mL) or ES-62 alone. Control wells
were incubated with medium alone (RPMI complete BMMC
medium supplemented with growth factor media 3% TOP3 and 1%
KLSC). Cells were incubated for 24 h at 37 ◦C/5% CO2. Following
this, samples were collected into 1.5 mL  sterile eppendorf tubes
and centrifuged at 500 g for 5 min. The supernatant was then
removed and the cells washed twice with sterile PBS (by centrifug-
ing at 500 g for 5 min). Cells were then re-suspended in 1 mL of
BMMC  complete medium supplemented with 3% TOP3- and 1%
KLSC-conditioned medium.
500 L of cells were then transferred to the appropriate well
in a 24 well plate forming a Basal (unstimulated) and a stimulated
well for each experimental condition. Cells were then stimulated by
addition of medium alone, 0.5 g/ml of DNP-HSA to cross-link FcRI
or 1 g/ml of LPS (Salmonella Minnesota; Sigma–Aldrich, Dorset,
U.K.). Cells were incubated for 24 h at 37
◦
C, 5% CO2. Reactions were
terminated after the desired culture period by centrifugation at
500 × g for 5 min  and supernatants aspirated for determination of
cytokine release. The resultant supernatant was stored at –20 ◦C
until required.
2.5. Cytokine analysis
Cytokine ELISAs for IL-6 and TNF- (limits of detection 15 pg/mL
for both; BD Biosciences) were performed on triplicate samples
according to the suppliers’ recommendations and developed using
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KPL Sureblue, TMB  Microwell Peroxidase Substrate. The reaction
was terminated by stop solution, 2N H2SO4. The ﬁnal reactions were
measured at 405 nm in an ELISA microplate reader.
2.6. Western blotting
Mast cells were washed in cold PBS by centrifugation (400 × g;
5 min) to terminate any reactions and/or to remove serum before
cell lysis. Untreated or stimulated cells (as described previously)
were lysed by the addition of 20–40 L (cell number dependent)
of modiﬁed Radio-Immunoprecipitation Assay (RIPA) buffer (RIPA
Buffer from SIGMA, USA). Modiﬁed RIPA buffer consisted of 100X
HALTTM Protease and Phosphatase Inhibitor cocktails (Thermo Sci-
entiﬁc, IL, USA) diluted 1 in 100 in RIPA buffer. After re-suspending
the cell pellet in modiﬁed RIPA buffer, cells were incubated on
ice for 15 min  to allow solubilization before centrifugation at
5000 × g for 10 min. The resultant supernatants containing the cell
lysates were stored at −80 ◦C for long-term storage or −20 ◦C for
short-term storage before being analysed by SDS-PAGE gel elec-
trophoresis and Western Blot analysis.
Equal protein loadings of cell lysates or control extracts
(30–40 g per lane for BMMCs  unless stated otherwise) deter-
mined by BCA protein assay (bicinchoninic acid, Thermo Scientiﬁc
Pierce) were resolved using XCell surelock Mini-cell kit with
NuPAGE® Novex® high-performance precast 4–12% Tris–Bis gels
and NuPAGE® buffers and reagents (Invitrogen). Proteins were then
transferred onto a Nitrocellulose membrane (Amersham) using
NuPAGE® transfer buffer supplemented with 10% methanol and
successful protein transfer was validated by Ponceau Red stain-
ing. Membranes were then washed in Tris–buffered saline (TBS)
(0.5 M NaCl and 20 mM Tris, pH 7.5) with 0.1% (v/v) Tween-
20 (TBS/Tween) and non-speciﬁc binding sites blocked for one
hour in TBS-Tween containing 5% non-fat milk protein (Marvel).
Membranes were then incubated with the appropriate primary
detection antibody overnight at 4 ◦C on a shaker. All antibodies
tested were either diluted in 5% non-fat milk or 5% BSA. Follow-
ing primary antibody incubation, nitrocellulose membranes were
washed as before and incubated in the appropriate HRP-conjugated
secondary antibody (diluted up to 1: 2500 in wash buffer contain-
ing 5% non-fat milk) for 1–2 h at room temperature. Nitrocellulose
membranes were then washed as before and protein bands visu-
alised using the NOVEX® ECL HRP Chemiluminescent detection
system (Invitrogen) and UltraCruzTM Autoradiography ﬁlm (Santa
Cruz biotechnology Inc, USA). Densitometry was  performed using
Image J software.
2.7. Statistical analysis
The data presented are representative of the stated number of
individual experiments involving the indicated statistical analysis
using Graphpad Prism software. The statistical analysis for cytokine
production was performed in Graphpad PRISM using either a one
way ANOVA or a two way ANOVA with Bonferoni post test where
*P < 0.05 **P  < 0.005 *** P < 0.001 **** P < 0.0001.
3. Results
3.1. The effect of PKC-isoform deﬁciency on maturation of bone
marrow-derived mast cells (BMMCs)
Following the in vitro development of BMMCs  from various PKC
isoform−/− and matched WT  mice, cells were examined for co-
expression of the mast cell surface markers, c-kit and FcRI as an
indication of their status as mast cells. Such analysis (Fig. 1 and
Table 1) suggested that the absence of any of these PKC isoforms
Table 1
Development of BMMCs  in vitro from PKC isoform−/− and matched WT mice: c-kit
and FcRI expression levels analysed by ﬂow cytometry for PKC– , -, - and –.
PKC isoform % c-Kit+ FcRI+ cell WT  % c-Kit+ FcRI+ cell KO
PKC- 86.0 92.0
PKC- 87.5 85.0
PKC- 87.0 95.5
PKC- 94.8 96.8
Table 2
Cytokine responses of BMMCs  in response to antigen mediated cross-linking of FcRI
or stimulation with LPS as summarised by the percentage (%) of the PKC isoform
deﬁcient BMMCs in comparison to their WT counterpart. Data are presented as the
mean value ± SEM from at least 3 independent experiments, except TNF- release
by  matched WT  and PKC-−/− BMMCs  following LPS stimulation where the data
presented are representative of two experiments and thus the mean is displayed
only. ND = not detected and – represents no change.
PKC- PKC- PKC- PKC-
IL-6: FcRI 71 ± 14% 20 ± 10% 152 ± 21% 158 ± 7%
IL-6: LPS 159 ± 8% 30 ± 9% 158 ± 4% –
TNF-: FcRI 55 ± 10% 11 ± 7% ND ND
TNF-: LPS – 30% 162 ± 5% –
individually does not prevent maturation of this subtype of mouse
mast cells from bone marrow progenitors in vitro.
3.2. The effect of PKC-isoform deﬁciency on FcRI-mediated
cytokine production by BMMCs
By contrast, these PKC isoforms appear to play important roles in
the regulation of pro-inﬂammatory cytokine secretion by BMMCs
in response to cross-linking of bound IgE antibodies by antigen:
for example, PKC-−/− BMMCs  produced signiﬁcantly less IL-6 and
TNF-, in comparison to their WT  counterparts (Fig. 2a and b; sum-
marised data values in Table 2). Interestingly therefore, although
there appeared to be very little IL-6 release following FcRI cross-
linking in BMMCs  from the matched littermate WT  mice, deﬁciency
in the PKC- isoform resulted in an increase in antigen-stimulated
IL-6 secretion (Fig. 2c; Table 2). Similarly, analysis of PKC-−/− and
WT BMMC  following antigen cross-linking of IgE revealed that IL-
6 production is increased by deﬁciency in PKC- (Fig. 2d; Table 2).
Unfortunately, no TNF- production could be detected in any of the
experiments using matched WT  and PKC-−/− (n = 4) or PKC-−/−
(n = 3) mice following antigen cross-linking (data not shown). How-
ever, as with PKC- deﬁciency, it was found that IL-6 and TNF−
secretion were signiﬁcantly decreased in PKC-−/− BMMCs  follow-
ing IgE cross-linking by antigen (Fig. 2e and f; Table 2) with indeed,
the loss of this novel isoform having a greater impact than that of
absence of PKC-.
Collectively these data suggested that whilst PKC- and  pro-
mote FcRI-mediated IL-6 production, this is suppressed by PKC-
and - suggesting the potential for reciprocal counter-regulation
of FcRI-mediate cytokine release from BMMCs by these PKC iso-
forms.
3.3. The effect of PKC-isoform deﬁciency on TLR4-mediated
cytokine production by BMMCs
Consistent with our previous report that various mast cell sub-
sets, including BMMCs, respond differentially to antigen-mediated
cross-linking of bound IgE (via FcRI) and LPS (via TLR4)-
stimulation [10], PKC isoform deﬁciency exhibited differential
effects on LPS versus antigen-stimulated cytokine production. Thus,
whilst PKC--deﬁciency led to reduced antigen-stimulated IL-6
responses, the opposite trend was witnessed for LPS-stimulated
production of this cytokine was signiﬁcantly enhanced in PKC-
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Fig. 1. Phenotyping of BMMCs  from PKC isoform−/− and matched WT  culture are shown in (a)–(c). Forward scatter (FSC) versus side scatter (SSC) parameters of KO BMMCs
allowing gating of live cells on the basis of their size and granularity, respectively (a). Mast cells gated as described in panel (a) were examined for their expression of c-kit
and  FcRI (relevant to appropriate isotype controls; data not shown) for both PKC isoform WT  (b) and PKC isoform −/− (c) cultures.
−/− cells in comparison to WT  cells (Fig. 3a; Table 2) suggesting
that PKC- regulation of BMMC  IL-6 production was  context-
dependent. Moreover, PKC- deﬁciency had no clear effect on
LPS-stimulated TNF- production by BMMCs  (data not shown),
indicating there is further differential regulation of IL-6 and TNF-
responses in such cells. Interestingly, therefore, PKC--deﬁciency
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Fig. 2. FcRI-mediated cytokine release by PKC isoform−/− and matched WT BMMCs. BMMCs were sensitized with murine anti-DNP IgE antibodies (IgE; 0.5 g/mL) for 24 h
then  stimulated with DNP-BSA to induce cross-linking (XL) for 24 h. Cell culture supernatants were harvested and cytokine levels of IL-6 and TNF- release were measured
by  ELISA from PKC isoform-deﬁcient and corresponding WT  cells: PKC- (a and b), PKC- (c), PKC- (d) and PKC- (e and f) (Means ± SD, n = 3). The data presented are single
experiments representative of at least 3 independent experiments apart from those involving PKC-−/− and PKC–−/− IL-6 release, which are representative of 2 individual
statistically signiﬁcant experiments. Statistical analysis was  by ANOVA with Bonferoni post test where *P < 0.05 **P  < 0.005 ***P < 0.001 ****P < 0.0001.
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Fig. 3. TLR-4-mediated cytokine release by PKC isoform−/− and matched WT BMMCs  (a: PKC-; b and c: PKC-; d and e: PKC-). BMMCs  were incubated with LPS (1 g/ml)
for  24 h. IL-6 and TNF- release were measured by ELISA. The data presented are single experiments representative of at least 3 independent experiments with the exception
of  those involving PKC-−/− TNF- release, which are representative of 2 experiments. Statistical analysis was  by ANOVA with Bonferoni post test where *P < 0.05 **P  < 0.005
***P  < 0.001 ****P < 0.0001.
resulted in reduced LPS-stimulated IL-6 (Fig. 3b and Table 2) and
TNF- (Fig. 3c and Table 2) production indicating that this PKC
isoform generally acts to promote BMMC  cytokine responses and
suggesting that PKC− and − mediate their effects via distinct
regulatory pathways. Moreover, and reﬂecting the proposed neg-
ative regulatory effect of PKC- on antigen-speciﬁc responses,
PKC--deﬁcient BMMCs  also showed signiﬁcantly enhanced LPS-
stimulated IL-6 secretion in comparison to WT  BMMCs  (Fig. 3d and
Table 2) and in this case, TNF- production was also signiﬁcantly
up-regulated in KO cells (Fig. 3e; Table 2) when compared to WT
control: collectively, these ﬁndings suggest that PKC- acts gener-
ally to suppress BMMC  cytokine production. However, by contrast,
PKC- deﬁciency did not substantially impact on LPS responses
(results not shown), suggesting its (negative) regulatory effects are
restricted to the FcRI pathway.
3.4. The ES-62 modulatory effect remains even in the absence of
PKC-˛
As alluded to previously, ES-62-mediated inhibition of cytokine
production by human mast cells and BMMCs  has been associ-
ated with PKC- degradation following cross-linking of bound
IgE receptor [10,13], and we also noted reduced levels of PKC-
 following exposure to ES-62 in the present study (results not
shown). These ﬁndings are consistent with the reduced levels
of antigen-stimulated IL-6 and TNF- found in PKC- deﬁcient
BMMCs. However, the nematode product was able to reduce IL-
6 (Fig. 4a) and TNF- (Fig. 4b) cytokine production in both WT  and
PKC- deﬁcient BMMCs  following FcRI-mediated cross-linking,
and although the reduced cytokine responses observed in the PKC-
−/− cells may  mimic  some of the effects of ES-62, these data
suggest that our previously observed down-regulation of PKC-
 [13; and results not shown] is not solely responsible for the
inhibitory effects of ES-62 on BMMC  responses. Indeed, if anything
loss of PKC- signalling potentiates the inhibitory actions of ES-
62, possibly indicating that some of the effects of ES-62 reﬂect
indirect consequences of PKC- deletion. Perhaps consistent with
this, we have observed that ES-62 also modulates expression of
other PKC-isoforms and signal transducers (e.g. PKC- and MyD88;
13) in BMMCs  that may  contribute to its induction of hypore-
sponsiveness in these cells. Moreover, we hypothesised that there
may  be some functional redundancy/adaptation of PKC isoforms
such as  and  in PKC-−/− cells that ES-62 can also target: for
example, although analysis showed that ES-62 could still inhibit
antigen-stimulated IL-6 production in PKC-−/− BMMCs (Fig. 4c)
this inhibition was  slight, perhaps reﬂecting that PKC- deﬁciency
alone could effectively account for the level of ES-62-mediated inhi-
bition observed in WT  cells with the residual inhibition by ES-62
in PKC-−/− cells reﬂecting additional targeting of PKC- or some
other signal transducer. Moreover, whilst consistent with its pro-
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Fig. 4. ES-62 modulatory effect in the absence of PKC- (a and b), PKC- (c) and PKC- (d). PKC isoform−/− and matched WT BMMCs  were sensitized with 500 ng/ml anti-DNP
IgE  (IgE) in the presence or absence of ES-62 (2 g/mL) for 24 h. Cells were then stimulated with 500 ng/mL DNP to induce cross-linking of FcRI (XL) for 24 h at 37◦C. Release
of  IL-6 (a, c and d) and TNF- (b) was measured by ELISA. The data presented are from a single experiment incorporating triplicate values. Statistical analysis was  by ANOVA
with  Bonferoni post test where *P < 0.05 **P < 0.005 ***P < 0.001 ****P < 0.0001.
posed role as a negative regulator of FcRI signalling in BMMCs,
PKC-deﬁciency results in enhanced IL-6 cytokine responses that
were suppressed by ES-62 (Fig. 4d): however, by contrast and
perhaps surprisingly given that PKC- appears to exhibit nega-
tive regulation of BMMC  cytokine production, ES-62 inhibition of
such responses was not consistently modulated by PKC- deﬁ-
ciency (results not shown). We  therefore investigated whether
ES-62 was mediating its suppressive effects on FcRI-mediated
cytokine responses by direct and indirect effects of PKC- degrada-
tion by determining the effects of PKC- deﬁciency on expression
of PKC- and this revealed strong upregulation of this negative
regulator (Fig. 5). Further support for an interacting network of
PKC signalling is provided by the ﬁnding that, reﬂecting the pro-
found suppression of antigen-stimulated cytokine production in
these cells, PKC- expression is strongly downregulated in PKC--
deﬁcient cells perhaps suggesting there is coordinate regulation of
these cytokine-promoting PKC isoforms in BMMCs  (Fig. 5). Collec-
tively, these data may  suggest that by downregulating PKC-, ES-62
both disrupts cytokine-promoting pathways and induces PKC--
mediated cytokine-suppressing pathways (Fig. 6).
4. Discussion
Exposure to antigen results in rapid FcRI-dependent mast cell
degranulation of pre-formed mediators such as cytokines, his-
tamine, prostaglandins and leukotrienes and the de novo synthesis
Fig. 5. The absence of a PKC isoform can have a knock-on effect on other PKC isoform
expression levels in BMMCs. Total protein extracts from PKC isoform−/− BMMCs
were analysed by Western Blotting for their expression of PKC- or PKC-. The
samples were also probed for -actin as a loading control.
of cytokines [22,23], responses that contribute to the symptoms
and clinical manifestations of allergic disorders such as asthma [24].
The parasitic worm-derived immunomodulator, ES-62 induces
mast cell hyporesponsisveness and can directly interfere with mast
cell-dependent hypersensitivity in the skin and lungs by blocking
key FcRI- and TLR4-coupled signals, such as calcium mobilization
and PKC- activation [10,13]. Our previous work on human BMMCs
showed that ES-62 interacted with TLR4 at the cell surface and this
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Fig. 6. Model of differential and interactive roles of PKC isoforms in mast cells. (a) The conventional PKC isoforms  and  along with the novel isoforms  and  exhibit
differential functional roles in mast cells with respect to both antigen-induced FcRI cross-linking and LPS stimulation. PKC- and PKC- serve similar functions through
promoting IL-6 cytokine secretion following antigen stimulation and this is somewhat counter-regulated by PKC- and . The speciﬁc role of a PKC isoform also appears to
be  context-dependent as, for example, PKC- acts as a negative regulator of IL-6 production in response to LPS/TLR-4 signalling yet PKC- positively regulates this cytokine
in  response to LPS. Unlike the other PKC isoforms, the role that PKC- plays in mast cell functional responses seems to be restricted to the FcRI pathway. (b) The signalling
mechanisms whereby ES-62 inhibits mast cell function have not been fully delineated, however, we  indicate that ES-62 targets key signals involved in mast cell activation
such  as PKC-. Through targeting this isoform, ES-62 may  also have an indirect effect on other PKC isoforms such as PKC- (a negative regulator of BMMC  responses) which
in  turn leads to a further reduction in the secretion of pro-inﬂammatory cytokines. We hypothesise that ES-62 may  also target PKC- as this isoform has not only been shown
to  be crucial for full mast cell activation, but it may  share redundant or similar roles to PKC-. Additionally, the expression levels of PKC- appear to regulate those of PKC-
and  therefore through targeting this isoform, ES-62 may  again be indirectly targeting a network of PKC isoforms that includes, but is not restricted to, PKC-.
lead to internalization of the complex followed by sequestration (by
an unknown mechanism) and subsequent degradation of PKC- via
a caveolae-lipid raft, non-proteosomal mechanism [13]. However,
ES-62 also causes degradation of PKC- in human mast cells but
this is via a ubiquitin-proteosome-dependent mechanism. Never-
theless, our studies on different mouse-derived mast cell subsets
indicate that both mechanisms of degradation can operate with
respect to PKC- [10] indicating the complexity of the process.
Further studies on different mast cell types with respect to PKC
isoform expression and function may  therefore be warranted. Addi-
tional support that down-regulation of PKC- plays a signiﬁcant
role in the ES-62-mediated hyporesponsiveness of mast cells, is
now provided by our studies using BMMCs  from PKC--deﬁcient
mice, that demonstrate important but counter-regulatory roles for
this PKC isoform in FcRI- and LPS/TLR-4 mediated IL-6 produc-
tion. Whilst our ﬁndings that PKC- promotes FcRI-responses
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are consistent with those from other groups (e.g. Ref 14), the dif-
ferential effects on FcRI/TLR4 signalling were unexpected, as a
previous study in BMMCs  deﬁcient in PKC-, - or indeed both
isoforms, suggested that such conventional isoforms did not mod-
ulate LPS signalling in mast cells [25]. Interestingly, this study did
not ﬁnd PKC- to be important for FcRI-mediated IL-6 produc-
tion either but as the authors measured cytokine release after 3 h
this may  reﬂect that this PKC isoform exerts its effects on the
de novo synthesis of cytokines, rather than on exocytosis of pre-
formed mediators. Likewise, PKC- isoforms have been reported to
promote FcRI-mediated IL-6 release [14,16,25] whereas our data
suggest PKC- acts to suppress both FcRI and LPS-stimulated pro-
duction, discrepancies that may  again be reconciled by the potential
differential regulation of degranulation of preformed cytokines and
de novo cytokine synthesis and secretion. Moreover, the lack of IL-
6 production in the PKC-−/− cells witnessed by Nechushtan was
overcome when the sensitisation step with IgE was  increased from
2 h to 4 days, suggesting that FcRI ligation by IgE alone modu-
lates mast cell signals and in our experiments we sensitise with IgE
overnight. Indeed, we have previously shown such IgE sensitisa-
tion to amplify LPS/TLR4 responses in mast cells [10]. Additionally,
the consequence of IgE-mediated mast cell activation is not only
dependent upon the amount of speciﬁc IgE present, but it can also
be modulated by the dose of the cross-linking antigen. Despite WT
and KO BMMCs  showing similar behaviour, Lessmann et al., wit-
nessed differential IL-6 release from both cell types when these
cells were stimulated with two different concentrations of anti-
gen. Interestingly, the lower concentration of DNP-HSA (20 ng/mL)
employed in the study provoked larger amounts of cytokine release
in comparison to the higher concentration (200 ng/mL) [26]. Thus,
it seems likely that the role of a PKC isoform is determined by
the response provoked by an allergen/stimulus and that this role
may  alter depending on which signalling pathway i.e. whether it
is the immediate inﬂammatory response (exocytosis) or the more
sustained response (de novo synthesis of cytokines) is activated.
It would appear that the role of a PKC isoform is therefore con-
text dependent; similar to the functional responses of mast cells
depending upon the stimuli they receive [10].
Although, and consistent with the idea that ES-62 mediates
at least some of its desensitising effects via downregulation of
PKC-, FcRI-mediated IL-6 and TNF- production was  substan-
tially reduced in PKC-deﬁcient BMMCs  and ES-62 could further
suppress the residual activity. This possibly reﬂected that ES-62
can additionally downregulate PKC- in BMMCs [10] and this iso-
form has also been shown to promote antigen-stimulated mast cell
responses [27,28]. However, PKC- and  are also expressed by
BMMCs  [14] and so we investigated their potential role in ES-62-
mediated BMMC  hyporesponsiveness. Like PKC-, and as reported
previously for RBL cells [29], we found PKC- to play an important
role in FcRI-mediated cytokine production in BMMCs, as indi-
cated by PKC-−/− cells releasing substantially reduced levels of
both IL-6 and TNF-. However, in contrast to what was observed in
PKC--deﬁcient cells, although ES-62 could still slightly suppress
the residual cytokine production by PKC-−/− BMMCs, essentially
all of the inhibition observed in WT  cells could be accounted for
by that resulting from PKC- deﬁciency suggesting that this iso-
form may  be an important target, either directly or indirectly in
BMMCs. Of note, it has previously been reported that PKC-−/− T
cells show a defective response to activation, which can lead to
increased apoptosis [30] but we found no evidence of increased
apoptosis of PKC-−/− BMMCs  relative to WT  control cells follow-
ing FcRI-mediated cross-linking or LPS exposure as measured by
7-AAD staining (results not shown). Thus, the deceased cytokine
responses observed with PKC-−/− BMMCs  is not due to cell death.
To date, the role of PKC- in mast cell biology has been rather
controversial with one study implicating a redundant role for this
isoform, as the loss of PKC- had no impact on IL-6 or TNF- pro-
duction [26]. However, our data are suggestive of this novel isoform
being a negative regulator of mast cell effector function follow-
ing antigen stimulation as we have shown that IL-6 production
was signiﬁcantly up-regulated in the KO cells stimulated via FcRI.
Interestingly therefore, two independent studies in RBL cells have
previously supported a role for PKC- as a negative regulator of
signalling events such as calcium mobilization and/or MAP  kinase
activation [15,31], and we have shown ES-62 to suppress FcRI-
mediated calcium mobilisation in both human and mouse mast
cells [10,13]. Of note, despite the increased IL-6 production in the
PKC-−/− cells, ES-62 was  still able to decrease the levels of the
cytokine.
Finally, as our studies suggest that PKC- and  can play redun-
dant or similar roles in promoting FcRI-mediated responses that
can potentially be counter-regulated by PKC- and/or -, we  inves-
tigated whether ES-62 may  exert its desensitising effects, either
directly or indirectly, by targeting this PKC network, by determining
the effect of PKC--deﬁciency on PKC- expression. Western blot
studies showed that PKC-−/− BMMCs  have substantially elevated
expression of PKC- in comparison to their wild-type counter-
parts raising the possibility that by directly acting to downregulate
the cytokine promoting effects of PKC-, ES-62 may  in a compen-
satory manner additionally upregulate a negative regulator, PKC-,
to more efﬁciently inhibit mast cell IL-6 cytokine responses. We
also tried to extend this type of analysis to the other PKC isoforms
but unfortunately could not detect them by blotting in BMMC  sam-
ples in spite of using several different antisera for each isoform and
successfully detecting them in appropriate positive control cells in
each case. We  can only conclude that these isoforms are expressed
in our BMMCs  from different genetic backgrounds at levels that are
below the levels of detection of the indicator system employed in
the blotting.
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